Marktanalyse - Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017

Global Markets Direct
03.2017
90 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome — Pipeline Review, H1 2017, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 3, 2, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome - Overview

Acute Respiratory Distress Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development

Altor BioScience Corp

Athersys Inc

Commence Bio Inc

Faron Pharmaceuticals Oy

GlaxoSmithKline Plc

Global Blood Therapeutics Inc

Hydra Biosciences Inc

Implicit Bioscience Ltd

Phylogica Ltd

Savara Inc

Silence Therapeutics Plc

Acute Respiratory Distress Syndrome - Drug Profiles

ALT-836 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-10901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-11006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBT-440 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2586881 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2862277 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05285401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-36 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-98 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1229 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Respiratory Distress Syndrome - Dormant Projects

Acute Respiratory Distress Syndrome - Discontinued Products

Acute Respiratory Distress Syndrome - Product Development Milestones

Featured News & Press Releases

Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation

Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial

Sep 03, 2016: Queen’s University Developing New Drug against Leading Causes of Death in the UK - Sepsis and Ards

May 25, 2016: First patient dosed in Savaras pivotal trial for PAP

Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation

Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS

Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome

Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP

Aug 09, 2015: Serendex to initiate first phase II clinical trial

Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November

May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced

May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases

May 10, 2015: Positive topline data from Serendex phase I clinical trial

Feb 27, 2015: Serendex submits phase I application

Feb 13, 2015: Serendex partners up with leading German lung center

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corp, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics Inc, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Phylogica Ltd, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H1 2017

Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H1 2017

Acute Respiratory Distress Syndrome - Dormant Projects, H1 2017

Acute Respiratory Distress Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017

Acute Respiratory Distress Syndrome - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus